SCHEMBL19706546

SCHEMBL19706546

CCC(=O)Nc1n[nH]c2nc(C)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 15/20 0.49
GSK3A P49840 5/20 0.49
CDK2 P24941 3/20 0.49
CDK1 P06493 2/20 0.49
LIMK1 P53667 2/20 0.49
CDK5 Q00535 2/20 0.49
DYRK1A Q13627 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
STK17A Q9UEE5 2/20 0.49
MAP4K4 O95819 1/20 0.49
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
GAA P10253 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
PLK4 O00444 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19706535 0.83 DYRK1A (0.52) GSK3BGSK3ACDK2CDK1LIMK1
SCHEMBL19699601 0.79 MAPK1 (0.41) GSK3BGSK3ACDK2CDK1LIMK1
SCHEMBL22239632 0.74 ADORA1 (0.44) GAAADORA2A
SCHEMBL4488169 0.71 GSK3B (0.82) GSK3BDYRK1A
SCHEMBL6491225 0.71 GSK3B (0.82) GSK3BHDAC1HDAC2HDAC8
SCHEMBL4489321 0.71 GSK3B (0.76) GSK3B
SCHEMBL17777124 0.70 ADORA2A (0.41) LMNAGAAADORA2A
SCHEMBL4487680 0.69 GSK3B (0.84) GSK3BGSK3AHDAC1HDAC2HDAC8
SCHEMBL10884409 0.69 KMT2A (0.46) GAAADORA2A
SCHEMBL26789526 0.68 GAA (0.46) LMNAL3MBTL1GAAADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 GSK3B 2322/4885GSK3A 3031/4885CDK2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.